Myocardial Inflammation Associated with RA Disease Activity
FDA Rejects Novartis Bid to Repurpose Inflammation Drug for Heart Attacks
Cardiovascular Disease Rate Differs Between SLE Patients of Different Races, Ethnicities
FDA Update: Romosozumab’s Uncertain Future; Plus Tocilizumab Approved for GCA
NSAIDs Increase MI Risk; Plus New Label Warnings for Canagliflozin
A Moving Target: Cardiovascular Risk & Rheumatic Disease
